Incidence of axi-cel AEs by V2Vt. Incidence of AEs (A) and cumulative incidence of CRS and ICANS resolved within 21 days of onset (B) by V2Vt in patients treated with axi-cel. ^aEvaluated based on events reported on the 100-day follow-up case-report form in patients from the CIBMTR registry PASS Cohort. ^bEvaluated among patients alive at day 30 after infusion in patients from the CIBMTR registry PASS cohort. AE, adverse event.